163 related articles for article (PubMed ID: 37775993)
41. IRF7 as an Immune-Related Prognostic Biomarker and Associated with Tumor Microenvironment in Low-Grade Glioma.
Peng S; Wang G; Cheng Z; Guo Z
Int J Gen Med; 2021; 14():4381-4393. PubMed ID: 34413671
[TBL] [Abstract][Full Text] [Related]
42. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Zhang Q; Hong J
Front Genet; 2020; 11():363. PubMed ID: 32351547
[TBL] [Abstract][Full Text] [Related]
43. Prognosis and immune features of pyroptosis-related RNA patterns in low-grade glioma.
Liu H; Tao T
Front Oncol; 2022; 12():1015850. PubMed ID: 36605437
[TBL] [Abstract][Full Text] [Related]
44. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas.
Luo C; Liu Z; Ye W; Liu F
Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164
[No Abstract] [Full Text] [Related]
45. Immune-Related Gene SERPINE1 Is a Novel Biomarker for Diffuse Lower-Grade Gliomas
Huang X; Zhang F; He D; Ji X; Gao J; Liu W; Wang Y; Liu Q; Xin T
Front Oncol; 2021; 11():646060. PubMed ID: 34094933
[TBL] [Abstract][Full Text] [Related]
46. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
Mou Y; Zhang L; Liu Z; Song X
BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
[TBL] [Abstract][Full Text] [Related]
47. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract][Full Text] [Related]
48. The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma.
Han Y; Zou C; Zhu C; Liu T; Shen S; Cheng P; Cheng W; Wu A
Front Genet; 2021; 12():718717. PubMed ID: 34925438
[No Abstract] [Full Text] [Related]
49. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.
Zhao J; Wang L; Wei B
Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843
[TBL] [Abstract][Full Text] [Related]
50. Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Guo F; Hong J
Front Genet; 2020; 11():441. PubMed ID: 32431729
[TBL] [Abstract][Full Text] [Related]
51. Exploring the Correlation of Abnormal CXCL9 Expression with Immune Infiltration in Glioma and Patient Prognosis Based on TCGA and GTEx Databases.
Liao Y; Liu B; Jin C; Liao X; Zhang Z
J Mol Neurosci; 2022 Dec; 72(12):2413-2424. PubMed ID: 36449138
[TBL] [Abstract][Full Text] [Related]
52. Identification and verification of the ferroptosis- and pyroptosis-associated prognostic signature for low-grade glioma.
Wang J; Ren J; Liu J; Zhang L; Yuan Q; Dong B
Bosn J Basic Med Sci; 2022 Sep; 22(5):728-750. PubMed ID: 35276059
[TBL] [Abstract][Full Text] [Related]
53. An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma.
Tang G; Peng J; Huo L; Yin W
BMC Bioinformatics; 2023 Jun; 24(1):225. PubMed ID: 37264314
[TBL] [Abstract][Full Text] [Related]
54. Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma.
Ji Q; Cai Y; Shrestha SM; Shen D; Zhao W; Shi R
Biomed Res Int; 2021; 2021():7430315. PubMed ID: 34722771
[TBL] [Abstract][Full Text] [Related]
55. Identification and validation of a three-gene signature as a candidate prognostic biomarker for lower grade glioma.
Xiao K; Liu Q; Peng G; Su J; Qin CY; Wang XY
PeerJ; 2020; 8():e8312. PubMed ID: 31921517
[TBL] [Abstract][Full Text] [Related]
56. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
57. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
Wu S; Miao K; Wang L; Ma Y; Wu X
Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
[TBL] [Abstract][Full Text] [Related]
58. Leveraging a gene signature associated with disulfidptosis identified by machine learning to forecast clinical outcomes, immunological heterogeneities, and potential therapeutic targets within lower-grade glioma.
Zhou Y; Cao Y; Liu W; Wang L; Kuang Y; Zhou Y; Chen Q; Cheng Z; Huang H; Zhang W; Jiang X; Wang B; Ren C
Front Immunol; 2023; 14():1294459. PubMed ID: 38162649
[TBL] [Abstract][Full Text] [Related]
59. Predictive Panel for Immunotherapy in Low-Grade Glioma.
Lv Q; Zhang Z; Fu H; Li D; Liu Y; Sun Y; Wu M
World Neurosurg; 2024 Mar; 183():e825-e837. PubMed ID: 38216032
[TBL] [Abstract][Full Text] [Related]
60. The prognostic and immunological role of MCM3 in pan-cancer and validation of prognosis in a clinical lower-grade glioma cohort.
Huang QR; Jiang Q; Tan JY; Nong RB; Yan J; Yang XW; Mo LG; Ling GY; Deng T; Gong YZ
Front Pharmacol; 2024; 15():1390615. PubMed ID: 38698811
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
